Texas State Board of Pharmacy reproposes wide-ranging sterile compounding rule revisions after extensive public comment

The Texas State Board of Pharmacy voted to repropose amendments to rule 291.133 governing sterile compounding, moving the package back out for public comment after a daylong staff presentation and extensive public comment from compounding pharmacists, trade groups and attorneys.

Board staff told members the package being reproposed implements the board—s November 5, 2024, proposals and was published in the Texas Register on Dec. 27, 2024; the Office of the Governor—s Regulatory Compliance Division issued a determinations letter on May 2, 2025, finding the amendments a reasonable exercise of the board—s authority to protect health and safety. The amendments cover definitions, personnel training and competency, environmental monitoring, categorization of compounded sterile preparations, beyond-use dating (BUD) rules, requirements for primary engineering controls and cleaning/disinfection protocols, and records and recall procedures.

Why it matters: The changes would affect how pharmacies that compound sterile products operate, how often staff must be retested, how many finished units must be sterility-tested, and the maximum batch sizes allowed. Pharmacy owners, hospital systems and large compounders said some provisions, especially those affecting BUDs and sterility/antimicrobial testing, would substantially increase costs and could curtail patient access in rural or small independent settings. Advocates for adoption said the changes align Texas rules with nationally recognized sterility standards and strengthen patient safety.

What the proposed amendments would do

- Definitions and structure: The package revises or adds definitions (e.g., anteroom, buffer room, designated person, restricted access barrier system, segregated compounding area) and replaces prior risk-level language with a category-based structure for continuing-education and competency requirements. Staff noted the rule text clarifies ISO classifications (ISO Class 5, 7 and 8) by particle counts for 0.5-micron particles per cubic meter and updates humidity and pressure requirements for primary engineering controls.

- Personnel competency and testing: The proposal specifies training in a pharmacy—s standard operating procedures (SOPs) for all people who perform or oversee compounding activities. It would require competency reevaluation at least every 12 months for all personnel categories, with media-fill (aseptic technique) testing every six months for personnel who actually compound. The draft also standardizes hand hygiene, garbing, gloved fingertip/thumb sampling and incubation requirements for those tests and applies some checks to non-compounding personnel who have direct oversight.

- Environmental monitoring and cleaning: Classified areas (ISO 5, 7, 8) would be subject to a risk-based sampling plan; the draft requires monthly surface sampling and sets action levels for surfaces and viable air sampling. The package requires investigations and corrective actions when action levels are exceeded and prescribes cleaning/disinfection routines for PECs (primary engineering controls), ceilings, walls, floors, shelving and pass-through chambers.

- Categories, batch sizes and BUDs: The rule would define three categories of compounded sterile preparations and set BUD frameworks tied to category, processing method (aseptic vs. terminal sterilization), dosage form (aqueous vs nonaqueous) and whether sterility testing is performed. The draft text cited by staff limits maximum batch size for preparations requiring sterility testing to 750 final-yield units, and it expands the immediate-use window (replacing a prior 1-hour administration rule with a requirement that administration begin no later than four hours following the start of preparation for immediate-use exemptions).

- Sterility testing and container requirements: The draft would require sterility testing on a sample equal to 5% of units produced for some categories and requires container-closure integrity evaluation where container-closure data are absent. The package also proposes antimicrobial effectiveness (preservative challenge) testing for certain multi-dose compounded sterile preparations.

Public comment and stakeholder concerns

Commenters represented a range of pharmacy interests, and their submissions highlighted three recurring themes: alignment with USP standards, operational costs and flexibility for small and automated operations.

- Jonathan Head, a compounding pharmacist and co-owner of Las Colinas Pharmacy, told the board that the draft—s fixed BUD caps for aqueous Category 3 products remove pharmacists— ability to extend dates based on formulation-specific stability data. He said his pharmacy spent "just over $120,000" on testing for two formulations and warned the proposed caps could force smaller operations to make more frequent, smaller batches or eliminate services. He also criticized the 5% sterility-testing requirement, saying it would nearly double the number of vials required to be tested for a 750-unit batch compared with the sample sizes in USP <71>, and suggested, "Texas adopt a testing cap of 20 vials per batch similar to the cap that's in USP 71."

- Empower Pharmacy representatives described high-volume semi- and fully automated filling systems and urged the board to allow larger batch sizes where validated automation and media-fill studies demonstrate sterility assurance. Jules D—Souza, director of quality operations at Empower, told the board: "Modern aseptic compounding has evolved significantly. At Empower, we operate semi-automated filling systems capable of producing up to 50 vials per minute... Limiting these systems to 750 units would unintentionally increase manual interventions and defeat the safety objective of the regulation."

- Several trade groups and associations supported many elements of the package but urged specific changes. The Texas Society of Health-System Pharmacists (TSHP) and other hospital-affiliated commenters urged alignment with USP <797>, saying "safe sterile compounding saves lives," and asked the board to adopt national patient-safety standards without deviation. The Alliance for Pharmacy Compounding, Texas Hospital Association and individual commenters recommended changes on sterility-testing methods, media-fill frequency and definitions.

- Attorneys and consultants representing compounding pharmacies warned of high compliance costs. One compounding regulatory consultant outlined a modeled preliminary-testing cost in the low tens of thousands per formulation and urged carve-outs for small-batch compounders; other speakers asked the board to preserve professional judgment and drug-specific science rather than imposing one-size-fits-all caps.

Board deliberations and staff directions

Board members discussed multiple technical and policy tradeoffs raised by commenters. Among the items flagged for further staff drafting and clarification before the reproposal were: - Whether to allow a higher maximum batch yield for products that are fully or primarily prepared and filled using validated automated compounding devices (board members asked staff to draft language to define the automation threshold and a potential higher cap for automated packaging), - Whether the 5% sterility-testing requirement should instead reference USP <71> sample tables or otherwise be capped for large batches, - How to treat small-batch Category 3 compounding (board members discussed carve-outs for batches below 24 units but sought guardrails to prevent routine fragmentation of large production into many small batches to evade testing), - Whether to retain or modify provisions requiring antimicrobial effectiveness testing and container-closure integrity testing for multi-dose compounded sterile preparations (several members asked staff to draft language allowing use of previously generated, validated data from recognized sources in lieu of repetitive per-formulation testing), and - Clarification and simplification of the language that distinguishes personnel who "perform compounding," those who "provide direct oversight," and those who do neither but perform in-process checks or restocking (the board asked staff to harmonize those provisions with SOP-based delegation language already in the draft).

Board action

After discussion, a board member moved to repropose the amendments incorporating the edits members had decided during the meeting; the motion was seconded and carried. The board instructed staff to prepare the reproposed text for publication and to incorporate the clarifications discussed above for public comment. The board also discussed—but did not finalize—specific numeric adjustments to batch-size caps and sterility-testing tables; those items were left for staff to draft and include in the reproposal.

What to watch next

- The board will publish the reproposed 291.133 language for public comment; stakeholders can expect staff-drafted alternatives on automation carve-outs, small-batch guardrails and permitted sources of preservative/closure data. - Because the package affects beyond-use dating, sterility testing and batch-size limits, pharmacies that compound sterile products should review the reproposed text when published and assess any data or validation work needed to preserve current services.

Speakers (selected)

- Iman [board staff], presenter, Texas State Board of Pharmacy staff (staff presenter) - Jonathan Head, compounding pharmacist and co-owner, Las Colinas Pharmacy - Jules D—Souza, director of quality operations, Empower Pharmacy - Frank Kratfl, director of pharmacy operations, Empower Pharmacy - Jordan Kuche, PIC, Empower Pharmacy (Houston 503A facility) - Steven Snow, compounding regulatory consulting attorney - Clint Narver, attorney, McGuireWoods (representing compounding pharmacies) - Cole Knudsen, practicing pharmacist, member of the board—s sterile compounding task force; speaking for TSHP - Representatives and commenters from: Alliance for Pharmacy Compounding, Texas Hospital Association, PCCA, Texas Society of Health-System Pharmacists

Authorities cited in discussion

- Texas Administrative Code rule cited by staff: 291.133 (proposed amendments) - Publication: Texas Register (12/27/2024 publication noted by staff) - United States Pharmacopeia (USP) standards cited repeatedly by commenters: USP <797> (sterile compounding) and USP <71> (sterility testing) - Office of the Governor, Regulatory Compliance Division (determination letter, 05/02/2025)

Ending note: The reproposal is not final policy. The board carried a motion to repropose the package, and staff were directed to prepare a reproposed draft that incorporates the meeting—s clarifications; that draft will be published for public comment before any final adoption or effective-date decision is made.